Genetic code with heart and muscle symbols

Unlocking the Mystery: How Your Genes Impact Statin Side Effects

Author's portrait.
Samir D’Costa in Health & Wellness December 2025 • 5 min read.

"New research reveals a crucial link between a specific gene variant and muscle pain in Chinese patients taking statins. Could personalized medicine be the key to safer cholesterol management?"


Statins are among the most widely prescribed medications for lowering cholesterol and reducing the risk of heart disease. While generally safe and effective, a significant number of patients experience muscle-related side effects, ranging from mild myalgia (muscle pain) to severe rhabdomyolysis (muscle breakdown). These side effects can lead to decreased adherence to medication or even discontinuation of statin therapy, thus undermining efforts to protect against cardiovascular events.

The variability in how individuals respond to statins has long puzzled researchers. While traditional clinical factors like age, sex, and the presence of diabetes can play a role, genetic variations are increasingly recognized as a crucial piece of the puzzle. Understanding these genetic factors could pave the way for personalized medicine approaches, where statin prescriptions are tailored to an individual's genetic makeup, minimizing the risk of side effects.

A recent study published in the European Journal of Clinical Pharmacology sheds new light on the link between a specific genetic variant and statin-induced myotoxicity in Chinese patients with coronary artery disease. The study focused on a variant in the SLCO1B1 gene, which plays a key role in how the body processes statins. The findings offer valuable insights into why some individuals are more susceptible to muscle-related side effects and how personalized medicine could help mitigate these risks.

Decoding the SLCO1B1 Gene: Your Body's Statin Transporter

Genetic code with heart and muscle symbols

The SLCO1B1 gene provides instructions for making a protein that helps transport statins into liver cells, where they can effectively lower cholesterol levels. However, variations in this gene can affect how efficiently the transporter protein works. One particular variant, known as 521T>C, has been previously linked to statin-induced muscle injury, particularly with simvastatin, in Caucasian populations. The 'C' allele reduces the protein’s efficiency, leading to increased statin concentrations in the blood and potentially causing muscle-related side effects.

This study sought to investigate whether the SLCO1B1 521T>C variant is also associated with statin-induced myotoxicity in Chinese patients. The researchers conducted a nested case-control study, comparing 148 Chinese patients experiencing statin-induced myotoxicity with 255 patients without muscle-related side effects. All participants had coronary artery disease (CAD).

  • Participants: Included 148 Chinese patients with statin-induced myotoxicity and 255 controls without side effects, all with coronary artery disease.
  • Genetic Analysis: Genotyped participants for five SNPs in CYP3A5, SLCO1B1, and APOE genes.
  • Focus: Assessed the impact of genetic variants on statin-induced myotoxicity.
  • Key Finding: Patients with at least one SLCO1B1 521C allele had a higher risk of myotoxicity (OR = 1.69, 95%CI = 1.07–2.67, P = 0.024).
The researchers found that Chinese patients carrying at least one copy of the 'C' allele had a significantly higher risk of developing myotoxicity compared to those without the variant. Further analysis revealed a particularly strong association between the 521C allele and myotoxicity in individuals taking rosuvastatin, one of the most commonly prescribed statins. Specifically, individuals with the 521C allele who were taking rosuvastatin had a 3.67 times higher risk of myotoxicity. No such association was observed with atorvastatin or simvastatin.

What Does This Mean for You? The Future of Personalized Statin Prescriptions

This study highlights the importance of genetic factors in determining an individual's response to statin therapy. While further research is needed, these findings suggest that genetic testing for the SLCO1B1 521T>C variant could help identify individuals at higher risk of developing myotoxicity, particularly those who are prescribed rosuvastatin. This information could then be used to guide statin selection and dosage, potentially minimizing the risk of side effects and improving patient adherence. As personalized medicine continues to advance, genetic testing may become a routine part of statin prescriptions, leading to safer and more effective cholesterol management for all.

About this Article -

This article was crafted using a human-AI hybrid and collaborative approach. AI assisted our team with initial drafting, research insights, identifying key questions, and image generation. Our human editors guided topic selection, defined the angle, structured the content, ensured factual accuracy and relevance, refined the tone, and conducted thorough editing to deliver helpful, high-quality information.See our About page for more information.

Everything You Need To Know

1

What are statins, and why is there so much interest in understanding their side effects?

Statins are medications prescribed to lower cholesterol and reduce the risk of heart disease. They are effective, but some individuals experience muscle-related side effects like myalgia or rhabdomyolysis. These side effects can negatively impact patient adherence and treatment outcomes. Understanding why these side effects occur is crucial for improving statin therapy.

2

What is the role of the SLCO1B1 gene in how statins work in the body?

The SLCO1B1 gene provides instructions for creating a protein responsible for transporting statins into liver cells, where they lower cholesterol. Variants in this gene, like the 521T>C variant, can affect the protein's efficiency. If the protein works less efficiently, statin concentrations in the blood increase, potentially leading to muscle-related side effects.

3

What were the main findings of the study on Chinese patients and statin-induced myotoxicity?

The study revealed that Chinese patients with coronary artery disease who carried at least one copy of the SLCO1B1 521C allele had a higher risk of developing myotoxicity when taking statins. This risk was particularly pronounced in individuals taking rosuvastatin. The findings suggest a link between this genetic variant and increased susceptibility to muscle-related side effects from statins.

4

What is the significance of the SLCO1B1 521T>C variant for personalized statin prescriptions?

The SLCO1B1 521T>C variant has a significant implication for personalized medicine. Identifying this genetic variant in individuals before statin prescription, especially rosuvastatin, can assess the risk of Myotoxicity. Dosage and selection of statins can be tailored to minimize side effects and improve the outcome.

5

Besides the SLCO1B1 gene, what other factors might contribute to statin-induced side effects?

While the study focused on the SLCO1B1 gene variant in Chinese patients with coronary artery disease, other genetic factors, such as variants in the CYP3A5 and APOE genes, can also influence an individual's response to statins. Additionally, clinical factors like age, sex, and the presence of diabetes can play a role. Further research is needed to fully understand the complex interplay of genetic and clinical factors in statin-induced side effects.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.